A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2006
11/30/2006	WO2006126673A1 Combined drug for treating diabetes
11/30/2006	WO2006126663A1 Pharmaceutical preparation for recovery from fatigue
11/30/2006	WO2006126654A1 Novel compound colletoic acid
11/30/2006	WO2006126541A1 Pharmaceutical composition comprising vitamin k
11/30/2006	WO2006126514A1 Arylacetate derivative having isoxazole skeleton
11/30/2006	WO2006126325A1 Agent having antiobesity activity and method of inhibiting obesity
11/30/2006	WO2006125972A1 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
11/30/2006	WO2006125958A1 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
11/30/2006	WO2006125778A1 Novel trifluoromethoxy-substituted aryl anilides
11/30/2006	WO2006125699A1 Method for lengthening the seasonal mobility period of fish
11/30/2006	WO2006113261A3 Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
11/30/2006	WO2006107902A3 Use of spirostenols to treat mitochondrial disorders
11/30/2006	WO2006100181A3 New salt and polymorphs of a dpp-iv inhibitor
11/30/2006	WO2006055625A3 Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
11/30/2006	WO2005080384A9 Benzimidazole derivative and use as aii receptor antagonist
11/30/2006	US20060270839 Crystallization of IGF-1
11/30/2006	US20060270718 e.g. N-(4-{1-Hydroxy-1-[1-(2-methoxyethyl)-1H-pyrrol-2-yl]-ethyl}-phenyl)-N-methyl-benzenesulfonamide; liver X receptor (LXR) agonist; antidiabetic, antiproliferative agent; lipid, metabolic disorders, obesity, diabetes, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia
11/30/2006	US20060270717 Therapeutic combination
11/30/2006	US20060270699 Stabilization of hypoxia inducible factor (HIF) alpha
11/30/2006	US20060270687 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states
11/30/2006	US20060270681 Pyridazine derivatives
11/30/2006	US20060270679 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/30/2006	US20060270676 Hydrazono-malonitriles
11/30/2006	US20060270665 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
11/30/2006	US20060270660 Processes for preparing substituted pyrimidines
11/30/2006	US20060270649 Azetidine derivatives, their preparation and medicaments containing them
11/30/2006	US20060270640 Method of preventing, medicating, and/or treating hypocalcemia of domestic mammal
11/30/2006	US20060269599 Fast-dissolving pharmaceutical composition
11/30/2006	US20060269581 Stable water in oil aminophylline emulsions
11/30/2006	US20060269565 Administering a polypeptide fused to an Fc, has T-cell proliferation inhibiting activity to treat autoimmune encephalomyelitis
11/30/2006	US20060269510 Orlistat compositions
11/30/2006	CA2726759A1 Human proislet peptide, derivatives and analogs thereof, and methods of using same
11/30/2006	CA2609506A1 Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
11/30/2006	CA2609454A1 Agent having antiobesity activity and method of inhibiting obesity
11/30/2006	CA2609446A1 Activator for peroxisome proliferator-activated receptor
11/30/2006	CA2609394A1 Pyrazole compound and therapeutic agent for diabetes comprising the same
11/30/2006	CA2609235A1 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
11/30/2006	CA2606902A1 Insulin resistance improver
11/30/2006	CA2606499A1 Thyromimetics for the treatment of fatty liver diseases
11/30/2006	CA2604771A1 Method for lengthening the seasonal mobility period of fish
11/29/2006	EP1726590A1 Cycloalkanopyridine derivative
11/29/2006	EP1726586A1 Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
11/29/2006	EP1726584A1 2-aminoquinazoline derivative
11/29/2006	EP1726583A2 Fluvastatin sodium crystal form LXXIX, processes for preparing it, compositions containing it and methods of using it.
11/29/2006	EP1726580A1 Aminophenylpropanoic acid derivative
11/29/2006	EP1726311A2 Migration of hematopoietic stem cells and progenitor cells to the liver
11/29/2006	EP1726217A1 Method for production of arachidonic acid
11/29/2006	EP1725555A1 Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
11/29/2006	EP1725543A1 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments
11/29/2006	EP1725231A1 Triazole, oxadiazole and thiadiazole derivatives as ppar modulators for the treatment of diabetes
11/29/2006	EP1648408A4 Azepine derivatives as pharmaceutical agents
11/29/2006	EP1597276A4 Therapeutic molecules
11/29/2006	EP1423708B1 Compositions and methods for aa4rp assay
11/29/2006	EP1409448B1 Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof
11/29/2006	EP1259223A4 Protein matrix materials, devices and methods of making and using thereof
11/29/2006	EP1248804B1 Recombinant antibodies to human interleukin-1 beta
11/29/2006	EP1248604B1 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
11/29/2006	EP1196598B1 Dsp-3 dual-specificity phosphatase
11/29/2006	EP1117692B1 Tie2 agonist antibodies
11/29/2006	EP0631505B2 Use of a peptide
11/29/2006	CN1871242A 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
11/29/2006	CN1871240A Pyrrolopyrimidine thion derivatives
11/29/2006	CN1871237A 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-IV inhibitors
11/29/2006	CN1871224A 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
11/29/2006	CN1871029A Drug containing chymase inhibitor as the active ingredient
11/29/2006	CN1870988A 2-azetidinones as anti-hypercholesterolemic agents
11/29/2006	CN1870986A Insulin secretion potentiator
11/29/2006	CN1870983A Compositions and foods for improving lipid metabolism
11/29/2006	CN1869208A Preparation of caterpillar fungus SOD and health-care product containing caterpillar fungus SOD
11/29/2006	CN1869207A Rat antihuman macrephage migration inhibiting factor monoclone antibody and its application
11/29/2006	CN1869033A Modifications of the trometamol salt of R-thioctic acid as well as a process for their production
11/29/2006	CN1868511A Compound prepn. contg. extractive of almond and extractive of ginkgo leaf
11/29/2006	CN1868492A Method for preparing capsule for preventing and treating cardiovascular and cerebrovascular diseases
11/29/2006	CN1868489A Vinegar with function of treating and preventing hyperlipemia
11/29/2006	CN1868463A Slow-release prepn. contg. alpha-lipoic acid or its derivatives, and preparing method therefor
11/29/2006	CN1868289A Milk mixed with additive for lowering blood sugar and its prodn. method
11/29/2006	CN1286844C Medicinal composition containing angiotensin II receptor antagonist and vitamin B
11/29/2006	CN1286822C Pyrimidinone compounds
11/29/2006	CN1286815C Novel 4-anilinoquinoline-3-carboxamides compound
11/29/2006	CN1286805C Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
11/29/2006	CN1286530C Self-regulated apoptosis of inflammatory cells by gene therapy
11/29/2006	CN1286524C Use of OPN for treatment and/or prevention of neurological diseases
11/29/2006	CN1286516C Biological nutrient for male and method for preparing capsule
11/29/2006	CN1286503C Combination of Chinese traditional medicine possessing function of regulating blood sugar, blood fat, preparation method
11/29/2006	CN1286479C Novel blood sugar lowering medicine and its preparing process
11/29/2006	CN1286456C Luolai compositions useful for the treatment of type-2 synalbumin diabetes pharmaceutical application
11/28/2006	US7141669 Cannabiniod receptor ligands and uses thereof
11/28/2006	US7141656 In situ screening, isolation of peptides; major histocompability complex
11/28/2006	US7141650 Polypeptide useful in screening of agents for improving insulin resistance and glucose metabolism; receptor binding assays; skeletal muscle protein
11/28/2006	US7141591 e.g., 2-methyl-2-{4-[3-(4-tert-Butyl-phenyl)-[1,2,4]oxadiazol-5-ylmethoxy]-2-methyl-phenoxy}propionic acid or its ethyl ester; dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, diabetes, anorexia, etc.
11/28/2006	US7141580 activity as prostaglandin E2 receptor antagonists
11/28/2006	US7141573 Huntington's diseases, Alzheimer's diseases, psychological disorders
11/28/2006	US7141572 For therapy of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS
11/28/2006	US7141563 Used for prophylaxis and therapy of central nervous system disorders, including obsessive-compulsive disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, panic disorder, migraine, sleep disorders
11/28/2006	US7141558 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
11/28/2006	US7141555 Water solubility, bioavailability, oral administration; unit dosage
11/28/2006	US7141547 Albumin fusion proteins comprising GLP-1 polypeptides
11/28/2006	US7141421 Control of metabolism with human 2-oxoglutarate carrier
11/28/2006	US7141363 Purposeful movement of human migratory cells away from an agent source
11/28/2006	US7141249 Rapidly soluble drug composition

1 ... 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 ... 1298